Novartis Shares Decline Following Safety Concerns Regarding Zolgensma Gene Therapy
Novartis (NVS) ADRs experienced a decline on Thursday following reports from patient advocates regarding potential safety issues linked to its gene therapy, Zolgensma. The concerns center on nine reported cases of tumors in children who received the one-time treatment for Spinal Muscular Atrophy. SMA Europe has acknowledged the information currently circulating regarding these medical findings. The development introduces regulatory and reputational risks for Novartis as stakeholders monitor whether these incidents are directly causal to the therapy, which could impact the long-term market position of its gene therapy portfolio.
Tickers: $NVS
Topics: adverse events drug safety gene therapy patient advocacy